ArticleCommunications biology2025
Acetyl-CoA carboxylase 1 knockdown promotes esophageal squamous cell carcinoma metastasis via the CXCL8-NET axis.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
- A novel secretory protein, circVEGFC-182aa, promotes esophageal squamous cell carcinoma progression by inducing M2 polarization of tumor-associated macrophages via regulating the TGF-β pathway.Journal of translational medicine · 2026Article
- Single-cell transcriptomic analysis of cutaneous squamous cell carcinoma identifies an NR1H3-associated angiogenic macrophage state.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) is associated with variable clinical outcomes, even among tumours with similar characteristics, complicating treatment. Here, we identify acetyl-CoA carboxylase 1 (ACC1), a key lipogenic enzyme, as a factor influencing this variability. Specifically, ACC1 knockdown in ESCC cells induces histone acetylation, activating c-Fos and C-X-C motif chemokine ligand 8 (CXCL8) transcription, which in turn promotes epithelial-mesenchymal transition (EMT) and enhances migration and invasion via CXCL8-C-X-C motif chemokine receptor 1/2 (CXCR1/2)-mediated PI3K/AKT and MEK/ERK signalling. Additionally, ACC1 knockdown stimulates neutrophil recruitment and neutrophil extracellular trap (NET) formation through CXCL8-dependent paracrine signalling, further enhancing tumour cell migration and invasion. In ESCC xenografts, ACC1 knockdown increases neutrophil infiltration and NET formation, accelerating metastasis. Clinically, low ACC1 expression and high CXCL8 levels are linked to poor prognosis in patients with ESCC, while NET formation further correlates with reduced survival. These findings highlight the ACC1-CXCL8-NET axis as a potential therapeutic target and prognostic marker in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.